New Alzheimer's drug shows promise in early trial
NCT ID NCT06774261
First seen Jun 01, 2026 · Last updated Jun 18, 2026 · Updated 3 times
Summary
This study tested a new drug called phenserine in 16 people with early or mild Alzheimer's disease. The goal was to see how it affects brain cell health and inflammation compared to the standard drug donepezil. Participants took the drug for 8 weeks and had regular checkups. The study focused on safety and changes in biomarkers, not on curing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stavanger University Hospital
Stavanger, Norway
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.